51 |
Protéolyse du facteur Willebrand et cardiopathies à forces de cisaillement élevées : nouvelles approches diagnostiques et thérapeutiques / VWF proteolysis and high-shear cardiovascular disorders : new diagnosis and therapeutic approachesRauch, Antoine 19 December 2014 (has links)
Protéolyse du facteur von Willebrand et cardiopathies à forces de cisaillement élevées: nouvelles approches diagnostiques et thérapeutiques Dans la première partie de ce travail, nous mettons en évidence l’intérêt d’une immunothérapie spécifique à base d’anticorps monoclonal pour la prévention de la dégradation du facteur von Willebrand (VWF) sous assistance circulatoire mécanique à flux continu. Via un anticorps monoclonal murin ciblant le domaine D4 du VWF et inhibant partiellement l’interaction VWF-ADAMTS13, une inhibition partielle de la dégradation du VWF est observée sur sang total dans un modèle ex-vivo d’assistance circulatoire mécanique.Dans la seconde partie, nous avons étudié l’influence de soudaines variations de l’intensité des forces de cisaillement sur la multimérisation du VWF dans 3 modèles in-vivo: un modèle lapin de sténose de l’aorte ascendante, à l’initiation d’une assistance ventriculaire gauche par une pompe à flux continu chez des patients en insuffisance cardiaque terminale et lors d’un remplacement valvulaire aortique par voie percutané chez des patients avec un rétrécissement aortique sévère. Les variations observées du profil multimérique sont très dynamiques survenant quelques minutes après les modifications des conditions de flux. Notre étude met ainsi en évidence une nouvelle application potentielle du VWF comme biomarqueur d’anomalies de flux dans les cardiopathies à forces de cisaillement élevées. Un monitoring en temps réel du VWF pourrait notamment avoir un intérêt en cardiologie interventionnelle pour les techniques percutanées utilisées pour le traitement du rétrécissement aortique.La dernière partie de ce travail porte sur le développement d’un test ELISA pour le diagnostic des formes acquises ou constitutionnelles de maladie de Willebrand secondaire à une protéolyse excessive du VWF par l’ADAMTS13. Ce test pourrait constituer une alternative intéressante aux actuelles méthodes électrophorétiques pour le diagnostic et la prise en charge de ces pathologies hémorragiques. / In the first part of the thesis, we describe a novel approach based on antibody-based therapy to prevent the acquired von Willebrand factor (VWF) degradation observed in continuous-flow mechanical circulatory assist device therapy. Via a murine monoclonal antibody directed against VWF D4 domain and thus interfering with VWF-ADAMTS13 binding, a partial inhibition of VWF degradation is observed in whole blood using an ex vivo circulatory assist device model. In the second part of the thesis, we investigated the relationship between acute changes in shear stress and variations in VWF multimeric profile in three distincts models in vivo: in a rabbit aortic banding model, in end-stage heart failure patients at initiation of continuous-flow ventricular assist device therapy and in severe aortic stenosis patients undergoing percutaneous aortic valve procedures. Variations in VWF multimeric profile in those settings are highly dynamic occuring within minutes after changes in shear stress status. Our study highlights that VWF could be used as a biomarker of blood flow in high shear cardiovascular disorders. A bedside VWF-monitoring could be of clinical interest in interventional cardiology for percutaneous aortic valve procedures used in severe aortic stenosis.The last part of the thesis focused on the development of an ELISA-based diagnosis of constitutive or acquired VWF disorders associated with an increased ADAMTS13-mediated VWF proteolysis. Such assay might represent an attractive alternative to electrophoresis-based assays in the diagnosis and management of such bleeding disorders.
|
52 |
Avaliação da expressão proteica e de alterações moleculares do receptor hepático LRP1 e sua correlação com os níveis plasmáticos de fator VIII / Evaluation of protein expression and molecular changes of hepatic LRP1 receptor and its correlation with plasma levels of factor VIIIBittar, Luis Fernando, 1980- 24 August 2018 (has links)
Orientador: Joyce Annichino-Bizzacchi / Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-24T06:24:29Z (GMT). No. of bitstreams: 1
Bittar_LuisFernando_D.pdf: 2765667 bytes, checksum: 034770d407c1c68eebc65646b23b7cc9 (MD5)
Previous issue date: 2013 / Resumo: Introdução: Aumento dos níveis de fator VIII (FVIII) é um fator de risco prevalente e independente para tromboembolismo venoso (TEV). Síndrome pós-trombótica (SPT) é uma complicação a longo prazo da trombose venosa profunda (TVP) de membros inferiores, que está presente em 20% -50% dos pacientes, e podem ser associados a um processo inflamatório crônico. O receptor low density lipoprotein receptor-related protein 1 (LRP1) tem sido associado ao catabolismo do FVIII. Metodologia: Após uma mediana de 10 anos do primeiro episódio trombótico, avaliamos os níveis de FVIII em 68 pacientes com TEV e níveis elevados prévios deste fator, e 67 controles saudáveis. Posteriormente, foi analisada a presença de SPT em pacientes e sua relação com os níveis plasmáticos de FVIII. Além disso, foram avaliadas as regiões dos genes do FVIII e do LRP1 que codificam as regiões de afinidade entre eles, com o objetivo de verificar se essas alterações moleculares estão associadas aos níveis plasmáticos de FVIII, e com o TEV. Por último, foi avaliada a expressão proteica de LRP1 no fígado de 20 pacientes cirúrgicos. Resultados: Após 10 anos do primeiro episódio de TEV, os níveis de FVIII foram significativamente maiores em pacientes quando comparados aos controles (158,0 UI / dL vs 126,1 UI / dL, p <0,001]. Pacientes com SPT grave apresentaram níveis aumentados de FVIII (182,0 UI / dL) quando comparados aos pacientes com SPT moderada (155,5 UI / dL, p <0,001) ou sem PTS (154,0 UI / dL, p <0,001). Apesar de encontrarmos 14 alterações moleculares nos genes do FVIII e do LRP1, não foi encontrada nenhuma relação entre essas alterações moleculares e os níveis plasmáticos de FVIII ou com o TEV. Além disso, não foi observada correlação entre a expressão do LRP1 nas células hepáticas e os níveis plasmáticos de FVIII. Conclusões: Nós demonstramos um aumento persistente dos níveis de FVIII em um subgrupo de pacientes com TEV, mas de uma magnitude muito menor após 10 anos do primeiro episódio de TEV. Além disso, observamos uma associação significativa entre o aumento dos níveis plasmáticos de FVIII e SPT grave / Abstract: Introduction: Increased levels of factor VIII (FVIII) are a prevalent and independent risk factor for venous thromboembolism (VTE). Post-thrombotic syndrome (PTS) is a long-term complication of deep venous thrombosis (DVT) of the lower limbs that is present in 20%-50% of patients and can be associated to a chronic inflammatory process. The low density lipoprotein receptor-related protein 1 (LRP1) has been associated with FVIII catabolism. Methodology: After a median of 10 years of the first thrombotic episode, we evaluated FVIII coagulation levels in 68 patients with VTE and previous high levels of FVIII and in 67 healthy controls. Subsequently, we analyzed the presence of PTS in patients and its relationship with plasma levels of FVIII. Moreover, we evaluated the regions of FVIII and LRP1 genes encoding regions of affinity between these proteins, with the objective of determining whether these molecular changes are associated with plasma levels of FVIII and VTE. Finally, we evaluated the protein expression of LRP1 in the liver of 20 surgical patients. Results: After 10-years median of the first VTE episode, FVIII levels were significantly higher in patients when compared to controls (158.0 IU/dL vs. 126.1 IU/dL; p<0.001]. Patients with severe PTS showed increased levels of FVIII (182.0 IU/dL) when compared to patients with moderate PTS (155.5 IU/dL; p<0.001) or no PTS (154.0 IU/dL; p<0.001). Despite we have found 14 molecular changes in the FVIII and LRP1 genes, no relationship was found between these molecular alterations and FVIII levels or VTE. Moreover, no correlation was observed between LRP1 expression in the liver cells and plasma FVIII levels. Conclusions: We demonstrated a persistent increase of FVIII levels in a subset of patients with VTE, but in a much lower magnitude after 10 years of the first VTE episode. Moreover, we observed a significant association between increased plasma FVIII levels and severe PTS / Doutorado / Biologia Estrutural, Celular, Molecular e do Desenvolvimento / Doutor em Fisiopatologia Medica
|
53 |
Régulation de la fonction plaquettaire par un aptamère dirigé contre le domaine A1 du facteur Von-WillebrandDandachli, Firas 07 1900 (has links)
Drs Dandachli and Arzamendi contributed equally to this work. / L’adhésion, l’activation et l’agrégation des plaquettes représentent les étapes initiales dans la formation du thrombus aux sites des lésions vasculaires. Malgré l’utilisation des médicaments antiplaquettaires comme l’Aspirine, le Plavix et les inhibiteurs de la glycoprotéine IIb/IIIa (GPIIb/IIIa), l’incidence de thrombus dans la maladie coronarienne aigue reste élevée. Le dommage aux artères coronaires induit l’exposition du collagène de la matrice sous-endothéliale et sa liaison au facteur Von-Willebrand (vWF). Ceci contribue au recrutement et à l’adhésion des plaquettes via la liaison du domaine A1 du vWF à la GPIb des plaquettes.
Nous avons postulé que l’inhibition de la liaison vWF/GPIb pourra représenter une stratégie efficace pour inhiber l’adhésion initiale des plaquettes et ainsi réduire la propagation du thrombus. L’objectif de notre étude était de déterminer le potentiel anti-thrombotique d’un inhibiteur du vWF.
L’aptamère dirigé contre le domaine A1 du vWF (ARC1779) a été développé et fourni par la compagnie Archemix. Son effet et celui du Reopro (abciximab, inhibiteur de la GPIIb/IIIa comme témoin positif) ont été testés en utilisant du sang provenant de 5 volontaires sains et de 27 patients coronariens traités avec l’Aspirine (inhibiteur du cyclo-oxygénase ou COX) et le Plavix (anti-récepteur de l’adénosine diphosphate ou ADP), en accord avec le comité d’éthique de l’ICM. Les plaquettes ont été marquées avec l’Indium-111 afin de pouvoir quantifier leur adhésion dans le sang complet sur des surfaces artérielles porcines dénudées. L’adhésion des plaquettes a été effectuée dans des chambres de perfusion sous des forces de cisaillement de 6974/sec pendant 15 minutes à 37 °C. L’activation plaquettaire, suite à l’étude de l’adhésion, a été évaluée par l’expression de la P-sélectine et du vWF par la cytométrie en flux. L’effet de l’ARC1779 a été également déterminé sur l’agrégation plaquettaire, dans le sang complet par impédance, induite par l’acide arachidonique (AA), l’ADP, la Ristocétine et le peptide agoniste du récepteur de la thrombine-1 (TRAP-1). L’adhésion des plaquettes a été également observée par microscopie électronique à balayage.
Dans un premier temps, nous avons trouvé que l’adhésion des plaquettes des volontaires sains à l’artère endommagée était élevée (80 x 106/cm2). Cette adhésion a été réduite significativement de plus que 90% par l’abciximab (100 nM) et d’une façon dose dépendante avec l’ARC1779 (25-250 nM). La perfusion du sang avec ou sans ARC1779 n’entraine pas une activation plaquettaire, telle que déterminée par l’expression de la P-sélectine et du vWF à la surface des plaquettes. Suite à ces résultats, l’étude avec le sang des patients a été poursuivie avec des doses de 25, 83 et 250 nM d’ARC1779. L’agrégation plaquettaire du sang des patients a été complètement inhibée en réponse à l’AA et à l’ADP, ce qui confirme que ces patients étaient bien traités avec l’Aspirine et le Plavix. L’adhésion des plaquettes aux surfaces artérielles endommagées a été réduite, chez les volontaires sains et les patients, d’une manière dépendante de la dose d’ARC1779, lorsqu’il était incubé avant la perfusion. Cependant, l’ARC1779 et aussi l’abciximab étaient sans effets significatifs sur l’adhésion plaquettaire, lorsqu’ils étaient ajoutés 10 minutes après la perfusion. L’inhibition de l’adhésion avec 25 nM d’ARC1779 était comparable à celle obtenue avec l’abciximab. Cependant, l’agrégation plaquettaire en réponse au TRAP-1 n’était pas affectée par l’ARC1779, alors qu’elle était complètement inhibée par l’abciximab.
L’ARC1779 est un inhibiteur spécifique de la liaison du vWF au GPIb des plaquettes. Il inhibe l’adhésion plaquettaire aux surfaces artérielles endommagées sans affecter l’agrégation plaquettaire et confère une protection anti-thrombotique similaire à l’abciximab. L’ARC1779 pourra être considéré comme un nouvel antiplaquettaire qui possède des propriétés anti-thrombotiques plus intéressantes que l’abciximab. / Anti-platelet therapy in coronary artery disease (CAD) patients reduces recurrent
athero-thrombosis, but at the cost of increased risk of bleeding. Because von Willebrand factor (vWF) functions predominantly in a high-shear environment, the vWF-specific aptamer, ARC1779 that blocks the binding of vWF A1-domain to platelet glycoprotein Ib, may deliver a site-specific anti-thrombotic effect while minimizing bleeding risk. We investigated the efficiency of ARC1779 on platelet activation, adhesion, and aggregation in
CAD patients on double anti-platelet therapy.
Blood from 27 patients taking aspirin and clopidogrel and 5 normal volunteers was
labeled with 111In-autologous platelets and perfused over denuded porcine arteries at high shear rate for 15 minutes. Blood was treated with either 25, 83 and 250 nM ARC1779; 100nM abciximab or placebo, 5 min before (upstream therapy) or 10 min after (downstream therapy) beginning the perfusion. Under upstream, but not downstream therapy, platelet adhesion was significantly reduced by ARC1779 at 83 and 250 nM and by abciximab vs. placebo (4.8, 3.8 and 2.9 vs. 7.3 platelets x 106/cm2, p <0.05). In contrast to abciximab,
ARC1779 did not significantly affect platelet aggregation in response to thrombin receptor activating peptide-1, arachidonic acid and adenosine diphosphate. In addition, ARC1779 was without any effect on P-selectin expression and platelet-leukocyte binding.
In conclusion, ARC1779 has comparable anti-thrombotic efficacy to abciximab
among CAD patients receiving aspirin and clopidogrel, but with lesser systemic effects on platelet activation and aggregation. These important proof-of-concept data form the framework for randomized clinical investigations of this novel anti-platelet therapy among
CAD patients.
|
54 |
Avaliação das variantes genéticas funcionais trombogênicas relacionadas ao receptor plaquetário P2Y12 e à metaloprotease ADAMTS13 em pacientes apresentando doença arterial coronariana / Functionally genetic thrombogenic variants related to P2Y12 platelet receptor and metaloprotease ADAMTS13 in coronary disease patientsSchettert, Isolmar Tadeu 18 April 2008 (has links)
Variantes genéticas trombogênicas podem aumentar o risco de eventos adversos em pacientes com coronariopatia crônica. Estudos prévios demonstraram que o Haplótipo H2 do gene do receptor P2Y12 apresenta uma maior agregação plaquetária e está associado com a presença de isquemia arterial periférica. A metaloprotease ADAMTS13 é responsável pela clivagem do fator de von Willebrand e recentemente foi associada com doença isquêmica coronariana. O objetivo deste trabalho foi avaliar o efeito das variantes genéticas funcionais trombogênicas dos Haplótipos H1 e H2 do receptor plaquetário P2Y12 e dos polimorfismos C1342G (Q448E), C1852G (P618A) e C2699T (A900V) da metaloprotease ADAMTS13 em 611 pacientes com doença arterial coronariana multiarterial com função ventricular preservada, acompanhados por um período de 05 anos no ensaio clínico do projeto MASS II (Medical, Angioplasty, or Surgery Study II) em relação aos eventos morte, infarto agudo do miocárdio, angina refratária necessitando um novo procedimento e acidente vascular cerebral. Neste estudo, a avaliação dos Haplótipos H1 e H2 nos pacientes do MASS II não encontrou diferença entre estes haplótipos e os eventos estudados. A análise dos polimorfismos da ADAMTS13 não encontrou associação entre os polimorfismos e os eventos estudados, exceto para a variante genética T2699 (Val900) que está associada com o evento morte (OR: 1,67 95%IC: 1-2,78, p= 0,049) e morte por causa cardiovascular (OR: 2,23 95%IC: 1,2-3,94, p=0,004) e apresenta uma diminuição na sobrevida livre de morte por causa cardíaca para os portadores do genótipo TT relacionado à este polimorfismo. A análise dos haplótipos e das combinações alélicas destes polimorfismos não apresentou associação com eventos ou com a sobrevida livre dos eventos nestes pacientes. / Thrombotic genetic variants could improve the risk of adverse events related to coronary arterial disease (CAD). P2Y12 platelet receptor H2 haplotype showed higher aggregation index and a positive association was described between such genetic variant and peripheral artery disease. DAMTS13 is a metaloprotease responsible to von Willebrand factor cleavage recently found correlated to CAD. We tested the genetic variants P2Y12 receptor H1 and H2 haplotypes and ADAMTS13 polymorphisms C1342G (Q448E), C1852G (P618A) and C2699T (A900V) in a group of 611 patients enrolled in the Medical, Angioplasty, or Surgery Study II (MASS II), a randomized trial comparing treatments for patients with coronary artery disease (CAD) and preserved left ventricular function in a follow up period of 05 years. The incidence of the end points of death and death from cardiac causes, myocardial infarction, refractory angina requiring revascularization and cerebrovascular accident was determined for P2Y12 H1 and H2 haplotypes and ADAMTS polymorphisms. In our study, we did not disclose any association between H1 or H2 haplotype groups regarding the incidence of any of the studied cardiovascular end-points. The association of ADAMTS13 genotypes and cardiovascular events did not showed any association between C1342G (Q448E), C1852G (P618A) variants and cardiovascular end points. Our date provide a strong association between T2699 variant and increased risk to death (OR: 1,67 CI: 1-2,78, p= 0,049) and cardiac death (OR: 2,23 CI: 1,2-3,94, p=0,004) in a population with CAD. The allelic combinations and haplotypes obtained from ADAMTS13 polymorphisms were not associated to cardiac end points and survival differences between MASS II patients.
|
55 |
Die Wirkung von niedrig dosiertem Desmopressin auf die durch Acetylsalicylsäure verlängerte Blutungszeit / The effect of low dosage desmopressin of the prolonged bleeding time by acetylsalicylsäureJürgensen, Brigitte 07 July 2010 (has links)
No description available.
|
56 |
Régulation de la fonction plaquettaire par un aptamère dirigé contre le domaine A1 du facteur Von-WillebrandDandachli, Firas 07 1900 (has links)
L’adhésion, l’activation et l’agrégation des plaquettes représentent les étapes initiales dans la formation du thrombus aux sites des lésions vasculaires. Malgré l’utilisation des médicaments antiplaquettaires comme l’Aspirine, le Plavix et les inhibiteurs de la glycoprotéine IIb/IIIa (GPIIb/IIIa), l’incidence de thrombus dans la maladie coronarienne aigue reste élevée. Le dommage aux artères coronaires induit l’exposition du collagène de la matrice sous-endothéliale et sa liaison au facteur Von-Willebrand (vWF). Ceci contribue au recrutement et à l’adhésion des plaquettes via la liaison du domaine A1 du vWF à la GPIb des plaquettes.
Nous avons postulé que l’inhibition de la liaison vWF/GPIb pourra représenter une stratégie efficace pour inhiber l’adhésion initiale des plaquettes et ainsi réduire la propagation du thrombus. L’objectif de notre étude était de déterminer le potentiel anti-thrombotique d’un inhibiteur du vWF.
L’aptamère dirigé contre le domaine A1 du vWF (ARC1779) a été développé et fourni par la compagnie Archemix. Son effet et celui du Reopro (abciximab, inhibiteur de la GPIIb/IIIa comme témoin positif) ont été testés en utilisant du sang provenant de 5 volontaires sains et de 27 patients coronariens traités avec l’Aspirine (inhibiteur du cyclo-oxygénase ou COX) et le Plavix (anti-récepteur de l’adénosine diphosphate ou ADP), en accord avec le comité d’éthique de l’ICM. Les plaquettes ont été marquées avec l’Indium-111 afin de pouvoir quantifier leur adhésion dans le sang complet sur des surfaces artérielles porcines dénudées. L’adhésion des plaquettes a été effectuée dans des chambres de perfusion sous des forces de cisaillement de 6974/sec pendant 15 minutes à 37 °C. L’activation plaquettaire, suite à l’étude de l’adhésion, a été évaluée par l’expression de la P-sélectine et du vWF par la cytométrie en flux. L’effet de l’ARC1779 a été également déterminé sur l’agrégation plaquettaire, dans le sang complet par impédance, induite par l’acide arachidonique (AA), l’ADP, la Ristocétine et le peptide agoniste du récepteur de la thrombine-1 (TRAP-1). L’adhésion des plaquettes a été également observée par microscopie électronique à balayage.
Dans un premier temps, nous avons trouvé que l’adhésion des plaquettes des volontaires sains à l’artère endommagée était élevée (80 x 106/cm2). Cette adhésion a été réduite significativement de plus que 90% par l’abciximab (100 nM) et d’une façon dose dépendante avec l’ARC1779 (25-250 nM). La perfusion du sang avec ou sans ARC1779 n’entraine pas une activation plaquettaire, telle que déterminée par l’expression de la P-sélectine et du vWF à la surface des plaquettes. Suite à ces résultats, l’étude avec le sang des patients a été poursuivie avec des doses de 25, 83 et 250 nM d’ARC1779. L’agrégation plaquettaire du sang des patients a été complètement inhibée en réponse à l’AA et à l’ADP, ce qui confirme que ces patients étaient bien traités avec l’Aspirine et le Plavix. L’adhésion des plaquettes aux surfaces artérielles endommagées a été réduite, chez les volontaires sains et les patients, d’une manière dépendante de la dose d’ARC1779, lorsqu’il était incubé avant la perfusion. Cependant, l’ARC1779 et aussi l’abciximab étaient sans effets significatifs sur l’adhésion plaquettaire, lorsqu’ils étaient ajoutés 10 minutes après la perfusion. L’inhibition de l’adhésion avec 25 nM d’ARC1779 était comparable à celle obtenue avec l’abciximab. Cependant, l’agrégation plaquettaire en réponse au TRAP-1 n’était pas affectée par l’ARC1779, alors qu’elle était complètement inhibée par l’abciximab.
L’ARC1779 est un inhibiteur spécifique de la liaison du vWF au GPIb des plaquettes. Il inhibe l’adhésion plaquettaire aux surfaces artérielles endommagées sans affecter l’agrégation plaquettaire et confère une protection anti-thrombotique similaire à l’abciximab. L’ARC1779 pourra être considéré comme un nouvel antiplaquettaire qui possède des propriétés anti-thrombotiques plus intéressantes que l’abciximab. / Anti-platelet therapy in coronary artery disease (CAD) patients reduces recurrent
athero-thrombosis, but at the cost of increased risk of bleeding. Because von Willebrand factor (vWF) functions predominantly in a high-shear environment, the vWF-specific aptamer, ARC1779 that blocks the binding of vWF A1-domain to platelet glycoprotein Ib, may deliver a site-specific anti-thrombotic effect while minimizing bleeding risk. We investigated the efficiency of ARC1779 on platelet activation, adhesion, and aggregation in
CAD patients on double anti-platelet therapy.
Blood from 27 patients taking aspirin and clopidogrel and 5 normal volunteers was
labeled with 111In-autologous platelets and perfused over denuded porcine arteries at high shear rate for 15 minutes. Blood was treated with either 25, 83 and 250 nM ARC1779; 100nM abciximab or placebo, 5 min before (upstream therapy) or 10 min after (downstream therapy) beginning the perfusion. Under upstream, but not downstream therapy, platelet adhesion was significantly reduced by ARC1779 at 83 and 250 nM and by abciximab vs. placebo (4.8, 3.8 and 2.9 vs. 7.3 platelets x 106/cm2, p <0.05). In contrast to abciximab,
ARC1779 did not significantly affect platelet aggregation in response to thrombin receptor activating peptide-1, arachidonic acid and adenosine diphosphate. In addition, ARC1779 was without any effect on P-selectin expression and platelet-leukocyte binding.
In conclusion, ARC1779 has comparable anti-thrombotic efficacy to abciximab
among CAD patients receiving aspirin and clopidogrel, but with lesser systemic effects on platelet activation and aggregation. These important proof-of-concept data form the framework for randomized clinical investigations of this novel anti-platelet therapy among
CAD patients. / Drs Dandachli and Arzamendi contributed equally to this work.
|
57 |
Enzimas que hidrolisam nucleotídeos de adenina em plaquetas, agregação plaquetária e polimorfismo do gene α2 da integrina α2β1 em pacientes com a doença de von willebrand / Enzymes that hydrolyze adenine nucleotides in platelets Platelet Aggregation and Polymorphisms in the α2 Gene of integrin α2β1 in patients with von Willebrand diseaseSantos, Karen Freitas 08 April 2009 (has links)
Von Willebrand disease (vWD) is one of the most common inherited bleeding diseases, caused by a qualitative or quantitative deficiency of the von Willebrand factor (vWF). vWF is a multimeric glycoprotein synthesized by megakaryocytes and endothelial cells and it is present in the subendothelial matrix, blood plasma, platelets
and endothelium. This glycoprotein represents an important role in thrombus formation by initiating platelet adhesion to sites of injury as well as platelet aggregation. The objective of this study was determine the activities of NTPDase (CD39), 5 -nucleotidase (EC 3.1.3.5, CD73) and Ectonucleotide Pyrophosphatase/Phosphodiesterase (E-NPP) enzymes in platelets patients from von Willebrand
disease and healthy patients, as well as ristocetin-induced platelet aggregation (RIPA) and polymorphisms of the α2 gene of the α2β1 integrin. The following groups
were studied: 14 patients diagnosed with vWD and 14 healthy patients for control group. For ristocetin-induced platelet aggregation was used a Platelet Rich Plasma
(PRP) and Platelet Poor Plasma (PPP), using a final concentration of ristocetin in 1.25mg/mL. The polymorphisms of the α2 gene was analyzed through the
Polymerase chain reaction (PCR), used for digestion of the PCR product of the Bgl II restriction site. NTPDase and E-NPP were decreased in platelets of patients with
vWD compared to the group control. Moreover, the activity of the enzyme 5'- nucleotidase was not statistically significant. The results of the RIPA were significantly reduced in patients with vWD compared with the control. The allelic frequencies among vWD patients were found to be 78.57% for 807C and 21.43% for 807T. Our results indicate an decreased NTPDase and E-NPP activities in platelets, may be related to the low adhesiveness of platelets in patients with vWD. The allelic frequency 807C predominant suggests, in agreement with other studies, this
polymorphism and factor characteristic of hemorrhagic manifestations in patients with DvW. / A doença de von Willebrand (DvW) é uma das mais comuns entre as doenças hemorrágicas, e é provocada por uma deficiência qualitativa ou quantitativa do fator de von Willebrand (FvW). O FvW é uma glicoproteína multimérica sintetizada por megacariócitos e células endoteliais e está presente no matriz subendotelial, no plasma sanguíneo, nas plaquetas e no endotélio. Esta glicoproteína desempenha
um papel importante na formação do trombo plaquetário, iniciando a adesão plaquetária ao local do dano vascular, bem como, a agregação plaquetária. O objetivo deste estudo foi determinar a atividade das enzimas NTPDase (EC 3.6.1.5,
CD39), 5'-nucleotidase (EC 3.1.3.5, CD73) e Ectonucleotideo
pirofasfatase/fosfodiesterase (E-NPP) em plaquetas de pacientes com a DvW e em plaquetas de pacientes saudáveis, bem como agregação plaquetária induzida pela ristocetina (RIPA) e o polimorfismo do gene α2 da integrina α2β1 da superfície de plaquetas. Os grupos foram divididos da seguinte forma: 14 pacientes diagnosticados com DvW e 14 pacientes saudáveis, para o grupo controle. Para a RIPA foram utilizados um Plasma Rico em Plaquetas (PRP) e um Plasma Pobre em
Plaquetas (PPP), utilizando-se uma concentração final de ristocetina de 1.25mg/mL. O polimorfismo do gene α2 foi analisado através da reação em cadeia de polimerase
(PCR), utilizando para a digestão do produto da PCR a enzima de restrição Bgl II. Constatou-se que a atividade das enzimas NTPDase e E-NPP foram reduzidas em plaquetas de pacientes com DvW comparadas ao grupo controle. Por outro lado, a
atividade da enzima 5'-nucleotidase não foi estatisticamente significativa. Os resultados para os RIPA foram significativamente reduzidos em pacientes com DvW
comparado com o controle. A freqüência alélica encontrada entre os pacientes com DvW foi de 78,57% para o alelo 807C e de 21,43% para o alelo 807T. Nossos resultados indicam que a redução da atividade da NTPDase e da E-NPP em
plaquetas pode estar relacionada à baixa adesividade das plaquetas em pacientes com DvW. A freqüência alélica 807C predominante sugere, de acordo com outros estudos, que este polimorfismo é fator característico das manifestações
hemorrágicas em pacientes portadores da DvW.
|
58 |
Avaliação das variantes genéticas funcionais trombogênicas relacionadas ao receptor plaquetário P2Y12 e à metaloprotease ADAMTS13 em pacientes apresentando doença arterial coronariana / Functionally genetic thrombogenic variants related to P2Y12 platelet receptor and metaloprotease ADAMTS13 in coronary disease patientsIsolmar Tadeu Schettert 18 April 2008 (has links)
Variantes genéticas trombogênicas podem aumentar o risco de eventos adversos em pacientes com coronariopatia crônica. Estudos prévios demonstraram que o Haplótipo H2 do gene do receptor P2Y12 apresenta uma maior agregação plaquetária e está associado com a presença de isquemia arterial periférica. A metaloprotease ADAMTS13 é responsável pela clivagem do fator de von Willebrand e recentemente foi associada com doença isquêmica coronariana. O objetivo deste trabalho foi avaliar o efeito das variantes genéticas funcionais trombogênicas dos Haplótipos H1 e H2 do receptor plaquetário P2Y12 e dos polimorfismos C1342G (Q448E), C1852G (P618A) e C2699T (A900V) da metaloprotease ADAMTS13 em 611 pacientes com doença arterial coronariana multiarterial com função ventricular preservada, acompanhados por um período de 05 anos no ensaio clínico do projeto MASS II (Medical, Angioplasty, or Surgery Study II) em relação aos eventos morte, infarto agudo do miocárdio, angina refratária necessitando um novo procedimento e acidente vascular cerebral. Neste estudo, a avaliação dos Haplótipos H1 e H2 nos pacientes do MASS II não encontrou diferença entre estes haplótipos e os eventos estudados. A análise dos polimorfismos da ADAMTS13 não encontrou associação entre os polimorfismos e os eventos estudados, exceto para a variante genética T2699 (Val900) que está associada com o evento morte (OR: 1,67 95%IC: 1-2,78, p= 0,049) e morte por causa cardiovascular (OR: 2,23 95%IC: 1,2-3,94, p=0,004) e apresenta uma diminuição na sobrevida livre de morte por causa cardíaca para os portadores do genótipo TT relacionado à este polimorfismo. A análise dos haplótipos e das combinações alélicas destes polimorfismos não apresentou associação com eventos ou com a sobrevida livre dos eventos nestes pacientes. / Thrombotic genetic variants could improve the risk of adverse events related to coronary arterial disease (CAD). P2Y12 platelet receptor H2 haplotype showed higher aggregation index and a positive association was described between such genetic variant and peripheral artery disease. DAMTS13 is a metaloprotease responsible to von Willebrand factor cleavage recently found correlated to CAD. We tested the genetic variants P2Y12 receptor H1 and H2 haplotypes and ADAMTS13 polymorphisms C1342G (Q448E), C1852G (P618A) and C2699T (A900V) in a group of 611 patients enrolled in the Medical, Angioplasty, or Surgery Study II (MASS II), a randomized trial comparing treatments for patients with coronary artery disease (CAD) and preserved left ventricular function in a follow up period of 05 years. The incidence of the end points of death and death from cardiac causes, myocardial infarction, refractory angina requiring revascularization and cerebrovascular accident was determined for P2Y12 H1 and H2 haplotypes and ADAMTS polymorphisms. In our study, we did not disclose any association between H1 or H2 haplotype groups regarding the incidence of any of the studied cardiovascular end-points. The association of ADAMTS13 genotypes and cardiovascular events did not showed any association between C1342G (Q448E), C1852G (P618A) variants and cardiovascular end points. Our date provide a strong association between T2699 variant and increased risk to death (OR: 1,67 CI: 1-2,78, p= 0,049) and cardiac death (OR: 2,23 CI: 1,2-3,94, p=0,004) in a population with CAD. The allelic combinations and haplotypes obtained from ADAMTS13 polymorphisms were not associated to cardiac end points and survival differences between MASS II patients.
|
59 |
Lung inflammation associated with acute necrotizing pancreatitis in dogs and mice2014 May 1900 (has links)
Acute necrotizing pancreatitis (ANP) is a common gastrointestinal cause of emergency admissions in dogs and humans and can lead to a systemic inflammatory response syndrome resulting in multiple organ dysfunction syndrome. Among the various complications associated with ANP, acute lung injury (ALI) or its more severe form, acute respiratory distress syndrome (ARDS), are major contributors leading to high mortality rates associated with severe acute pancreatitis (AP) in human patients. The incidence of ALI/ARDS in ANP dogs is not well characterized. However, signs of respiratory complications have been reported clinically in dogs suffering from AP. The pathophysiology of ANP and its systemic complications in dogs and humans are not well understood. Most of the data related to AP comes from rodent models of AP, which may not always represent the true mechanisms occurring in the lungs of dogs or humans with ANP.
I decided to undertake evaluation of pancreas and lungs from dogs (N=21) that died of ANP. The cases were selected through the search of the medical records of the Veterinary Medical Center of the Western College of Veterinary Medicine (WCVM). Six healthy SPCA dogs were used as controls. The histology of pancreas was first graded to record the range of ANP severities within dog cases included in this study. Then, characterization of lung inflammation was done with histological grading and qualitative analysis of immunohistochemical staining for von Willebrand Factor (vWF), Toll-Like Receptor-4 (TLR4), interleukin-6 (IL6), and inducible nitric oxide synthase (iNOS). Quantification of the recruitment of septal macrophages in the lungs, designated as pulmonary intravascular macrophages (PIMs), in ANP dogs was achieved by counting the number of positive cells in alveolar septa using a macrophage antibody (MAC387). The results revealed that dogs suffering from ANP have variable lung inflammation, which was characterized by a significant infiltration of mononuclear phagocyte cells in the alveolar septa of all ANP dogs (median, 138; range 31-935) compared to control dogs (median: 1.5; range 0-16; p < 0.001), which suggested that PIMs are induced in ANP. In addition, robust staining for vWF in alveolar septal capillaries in lungs of ANP dogs suggested a strong microvascular inflammatory response. Finally, TLR4, IL6, and iNOS expression was increased in lungs of ANP dogs compared to control dogs.
The second study was to investigate whether PIMs are induced in a mouse model of L-arginine-induced ANP. Therefore, lungs of L-arginine treated mice (n=7 per time point) were evaluated at various time points (24 hours, 72 hours and 120 hours) using histology and immunohistochemical staining for CD68 cells and vWF. Nine control mice were used. Counting of CD68-positive cells in the lungs of mice treated with L-arginine showed increased numbers of mononuclear phagocytes in alveolar septa at every time point (p<0.001). Also, the lung’s vasculature from L-arginine-treated mice showed increased vWF staining.
Taken together, the data showed that ANP in dogs caused significant recruitment of PIMs, increased expression of vWF, TLR4, IL-6, and iNOS suggesting presence of lung inflammation. The mouse model of L-arginine-induced ANP also showed recruitment of PIMs and increased vascular expression of vWF suggesting that this model may be relevant to study the mechanisms of PIMs recruitment and their functions in lung physiology associated with ANP.
|
60 |
Doença de von Willebrand em cães : estudo da prevalência e caracterização da doença em cães normais e fêmeas durante o ciclo estral, gestação e lactação /Mattoso, Cláudio Roberto Scabelo. January 2010 (has links)
Resumo: A Doença de von Willebrand (DvW) é o distúrbio hemostático hereditário mais comum nos homens e também nos cães. A DvW já foi diagnosticada em mais de 54 raças de cães nos EUA. A DvW é causada por um defeito quantitativo e/ou qualitativo do Fator de von Willebrand (FvW), e nos cães é dividida em 3 tipos, tipo I, II e III. O diagnóstico da DvW está baseado na quantificação do FvW plasmático e testes de função plaquetária dependentes do FvW. Esse estudo foi dividido em duas partes, avaliação da prevalência da DvW (parte I) e avaliação das alterações do FvW em cadelas gestantes, e durante diferentes estágios do ciclo reprodutivo, em cadelas não gestantes (parte II). Os objetivos da parte I foram determinar a prevalência da Doença de von Willebrand (DvW) em cães da região de Botucatu, São Paulo, Brasil, e avaliar os testes laboratoriais para diagnóstico desta doença. Foram utilizados 350 cães de variadas idades e raças, de ambos os sexos. Os animais utilizados no estudo não tinham histórico ou evidências clínicas de alterações hemostáticas. Foram realizados os seguintes testes: antígeno do Fator de von Willebrand (vWF:Ag), Tempo de sangramento da Mucosa Oral (TSMO), Tempo de tromboplastina parcial ativada (TTPa) e atividade do Fator VIII (FVIII). A prevalência encontrada para Doença de von Willebrand em cães da região de Botucatu foi de 1,43%. A determinação do vWF:Ag foi o melhor teste laboratorial para diagnosticar a DvW. Os objetivos da parte II foram a avaliação das alterações encontradas na concentração do FvW em cadelas gestantes, e também durante diferentes estágios do ciclo reprodutivo, observados após a gestação, em animais portadores e não portadores para a DvW, além da avaliação de correlação entre FvW e cortisol. Foram utilizadas 7 cadelas portadoras (GI) e 9 não portadoras (GII) para DvW. Os animais foram... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Von Willebrand disease (vWD) is the most common inherited hemostatic disturbance affecting men and also dogs. It has already been diagnosed in more than 54 dog breeds in the USA. vWD is caused by a quantitative and/or qualitative defect in von Willebrand Factor (vWF); in dogs, it is divided into types I, II and III. The diagnosis of vWD is based on plasma vWF quantification and vWF-dependent platelet function tests. This study was divided in two sections, evaluation of vWF prevalence (Section I) and evaluation of vWF concentrations in pregnant bitches, and during various reproductive cycle stages in nonpregnant bitches (section II). The aims of (section I) were to assess the prevalence of von Willebrand disease in dogs from the region of Botucatu, São Paulo State, Brazil, and to evaluate diagnostic tests. The study included 350 dogs of various ages, different breeds, and both sexes. Dogs included in the study had no historical or clinical evidence of abnormal bleeding. von Willebrand factor antigen (vWF:Ag), Buccal mucosal bleeding time (BMBT), Activated partial thromboplastin time (aPTT), and Factor VIII activity (FVIII) were evaluated in their ability to diagnose vWD. The prevalence of vWD in dogs was 1.43% in the Botucatu region of Brazil. Determination of vWF:Ag was the best laboratory test to diagnose vWD. The aims of section II were the evaluation of vWF concentrations in pregnant bitches, and during various reproductive cycle stages in non-pregnant bitches, observed after the pregnancy in vWD affected and unaffected bitches, over there of the correlation among vWF and cortisol. Were used seven bitches affected (GI) and nine unaffected (GII) to vWD. Animals were evaluated during the pregnancy, parturition, lactation, and during various reproductive cycle stages in non-pregnant bitches. vWF concentration did not change during reproductive cycle stages in non-pregnant bitches... (Complete abstract click electronic access below) / Orientador: Regina Kiomi Takahira / Coorientador: João Pessoa Araujo Junior / Banca: Raimundo Souza Lopes / Banca: Luiz Henrique de Araújo Machado / Banca: Mere Erika Saito / Banca: Paulo Ricardo de Oliveira Paes / Doutor
|
Page generated in 0.3626 seconds